Which diseases can Ixazomib (Enleri) be used to treat and its efficacy evaluation?

Ixazomib is an oral reversible proteasome inhibitor mainly used to treat hematological malignancies such as multiple myeloma (MM). It exerts anti-tumor effects by selectively inhibiting the activity of the 20S proteasome, interfering with the protein degradation process of tumor cells, leading to the accumulation of abnormal proteins and inducing tumor cell apoptosis. Due to the convenience of oral administration, ixazomib has significant advantages in patient compliance compared with traditional injectable proteasome inhibitors, and also provides a feasible solution for long-term maintenance treatment.

In clinical application, ixazomib is often used in combination with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone) to form the IRd regimen for patients with relapsed or refractory multiple myeloma who have received at least one treatment in the past. Multiple clinical trials have shown that this combination regimen can significantly prolong progression-free survival (PFS). Some research data show that the median PFS can reach more than 20 months, which is better than dexamethasone alone or traditional therapy. Combination therapy can also improve the response rate (Overall Response Rate, ORR), and some patients even achieve complete remission (CR), showing the reliability of its efficacy in patients with relapsed or refractory MM.

Ixazomib has also shown promise in clinical trials for patients with newly diagnosed multiple myeloma. As a maintenance therapy, ixazomib can delay disease progression and reduce the risk of relapse, while oral administration reduces the burden of hospitalization and intravenous infusion. Studies have shown that the overall survival (OS) of patients treated with maintenance therapy is prolonged and is well tolerated. Adverse events mainly include mild to moderate gastrointestinal reactions, hematological toxicity and peripheral neuropathy, which can usually be alleviated through dose adjustment or symptomatic treatment.

Overall, ixazomib has significant efficacy and good safety in the treatment of multiple myeloma. Its oral administration feature improves patient compliance, and regimens combined with other drugs can significantly extend progression-free survival and overall survival while alleviating symptoms. Clinical feedback shows that most patients have significant disease control effects and improved quality of life after receiving ixazomib treatment, providing a safe, effective and convenient treatment option for patients with multiple myeloma.

Reference materials:https://www.drugs.com/